相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular Actions of Incretin-Based Therapies
John R. Ussher et al.
CIRCULATION RESEARCH (2014)
Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1
Jenny Tong et al.
DIABETES (2014)
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Guillermo Umpierrez et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
Michael Nauck et al.
DIABETES CARE (2014)
Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
Y. G. Kim et al.
DIABETES OBESITY & METABOLISM (2014)
Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
Yasuo Terauchi et al.
ENDOCRINE JOURNAL (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
Linong Ji et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
Louise E. Robinson et al.
BMJ OPEN (2013)
Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
Changting Xiao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study
Nobuya Inagaki et al.
CLINICAL THERAPEUTICS (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
Hari Hendarto et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
The once-daily human glucagon-like peptide-1 analog, liraglutide, improves ß-cell function in Japanese patients with type 2 diabetes
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2010)
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
Wolfgang Glaesner et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
General Multistage Gatekeeping Procedures
Alex Dmitrienko et al.
BIOMETRICAL JOURNAL (2008)
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
Y. Seino et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells
Y Anini et al.
ENDOCRINOLOGY (2003)
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
DG Parkes et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
分享论文
